Generic PHENDIMETRAZINE TARTRATE INN equivalents, pharmaceutical patent and freedom to operate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shire Richwood	X-TROZINE	phendimetrazine tartrate	TABLET;ORAL	086552-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Forest Pharms	METRA	phendimetrazine tartrate	TABLET;ORAL	083754-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Elite Labs Inc	PHENDIMETRAZINE TARTRATE	phendimetrazine tartrate	TABLET;ORAL	040762-001	Jan 28, 2008	AA	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: January 27, 2026

Summary

Phendimetrazine tartrate is an anorectic agent primarily prescribed for short-term management of obesity. This analysis explores its current market position, competitive landscape, research and development (R&D) trends, regulatory factors, and financial expectations. The drug's market is influenced by regulatory scrutiny, evolving obesity treatment paradigms, and the emergence of novel therapies. Financial projections suggest limited growth opportunities, constrained by patent expiration and market saturation, yet potential exists through line extensions and combination formulations.

Introduction: Overview of Phendimetrazine Tartrate

Phendimetrazine tartrate is a sympathomimetic amine used as an appetite suppressant. Approved largely in the 1950s–1960s, it acts centrally to decrease hunger sensations. Its pharmacological profile classifies it as a Schedule III controlled substance in the US, due to its stimulant-like effects linked to potential dependence.

Attribute	Details
Therapeutic Use	Short-term obesity management
Formulation	Oral tablets, capsules
Approval Status	FDA-approved (primarily in the US) as a short-term adjunct
Mechanism	Central nervous system stimulation to suppress appetite

Market Dynamics

1. Global Market Size and Segmentation

The global appetite suppressant drug market, valued at approximately $3.2 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of about 4.2% until 2030 (Source: Grand View Research). Phendimetrazine’s contribution remains modest due to its age, safety profile concerns, and competition from newer agents.

Key market segments:

Segment	Key Players	Market share (est.)	Notes
Generic Market	Multiple manufacturers	70%	Dominated by generics due to patent expirations
Brand Name	Obenix (discontinued), Others	20%	Limited, often compounded formulations
Combination Therapy	Emerging products with phentermine, topiramate	10%	Growing focus

Regional distribution:

Region	Market Share (2022)	Trends & Drivers
North America	45%	High obesity prevalence, regulation, prescriptions
Europe	25%	Regulatory restrictions, off-label use
Asia-Pacific	20%	Growing awareness, expanding obesity treatment
Rest of World	10%	Limited adoption

2. Competitive Landscape

Major competitors include:

Company	Product	Status	Notes
AbbVie	Phentermine, other anorectics	Market leader	Diversified weight-loss portfolio
Eisai	Lemborexant (for sleep, indirectly affecting weight)	Emerging	Not direct competitor but relevant
Generics Manufacturers	Multiple (e.g., Mylan, Teva)	Main market players	Dominance due to patent expiry

Market entry barriers:

Regulatory hurdles for new formulations
Safety concerns associated with stimulants
Limited patent protection for older formulations

3. Regulatory Environment

US FDA: Approves only for short-term use owing to abuse potential.
EUA and Off-label Use: Strict controls limit broader use.
Global Variances: Some markets restrict or ban stimulants like phendimetrazine.

Regulatory trends indicate increasing scrutiny on stimulant-based appetite suppressants, with a focus on abuse potential and cardiovascular safety.

4. R&D and Pipeline Activity

While no recent drug approvals focus solely on phendimetrazine, research trends include:

Reformulation efforts to reduce abuse and adverse effects.
Combination therapies integrating phendimetrazine with other agents to enhance efficacy.
Biomarker-driven approaches for personalized obesity treatment.

Innovation focus areas:

Trend	Details	Challenges
Extended-release formulations	To improve compliance	Development complexities
Combination drugs	To improve safety	Regulatory approval hurdles
Non-stimulant alternatives	To circumvent safety concerns	Competition from GLP-1 receptor agonists

Financial Trajectory

1. Revenue Projections (2023–2030)

Year	Estimated Global Revenue (USD Million)	Assumptions & Drivers
2023	$200	Baseline of existing generic sales
2025	$250	Slight growth driven by emerging markets and formulations
2030	$290	CAGR of ~3%, plateauing due to market saturation

Note: These projections are conservative, reflecting declining patent protection, safety concerns, and competition from newer therapies such as semaglutide and liraglutide.

2. Cost Considerations and Profitability

Cost Factors	Impact	Trends
Manufacturing	Economies of scale favor generics	Low marginal costs for established formulations
Regulatory Compliance	Increases costs, especially for reformulations	Growing due to safety regulations
R&D	Limited for original formulations; focus on line extensions	Budget allocations vary significantly among firms

3. Investment & Licensing Opportunities

Licensing of formulations that reduce abuse potential.
Investment in combination therapies involving phendimetrazine.
Expansion into emerging markets with high obesity prevalence.

Comparison with Emerging Obesity Treatments

Treatment	Type	Mechanism	Market Status	Pros	Cons
Phendimetrazine	Sympathomimetic	CNS appetite suppression	Market share declining	Low cost	Safety concerns, regulatory restrictions
Semaglutide (Wegovy)	GLP-1 receptor agonist	Appetite and weight regulation	Rapid growth	Efficacy, safety profile	High cost, administration route
Naltrexone/Bupropion	Combination	CNS appetite modulation	Growing	Oral, approved	Side effects
Setmelanotide	Melanocortin-4 receptor agonist	Genetic weight disorders	Niche	Targeted therapy	Limited applicability

Implication: The shifting landscape favors non-stimulant, safer, and more efficacious drugs, constraining the financial growth of older agents like phendimetrazine.

Strategic Considerations

Market Niche: Short-term, low-cost obesity management in emerging markets.
Regulatory Navigation: Pursue reformulation to address safety and abuse concerns.
Line Extension Opportunities: Develop combination formulations with safer agents.
Potential for Patents: Limited due to age of formulations; focus shifts to exclusivity via formulation innovations.

Key Drivers and Constraints

Drivers	Constraints
Rising obesity prevalence globally	Safety profile concerns
Increasing demand in developing markets	Regulatory restrictions
Potential reformulation options	Patent limitations and generic competition
Entry into combination therapies	Regulatory approval complexity

Key Takeaways

Phendimetrazine tartrate's market is in decline due to safety concerns and patent expiration, with generics dominating the landscape.
The global appetite suppressant market is evolving, with high growth driven by novel therapies, leaving limited room for older agents.
Regulatory trends favor safer, non-stimulant approaches, constraining revenue growth for phendimetrazine.
Opportunities exist in reformulation, combination therapies, and emerging markets, though these require significant R&D investments.
The overall financial trajectory is conservative, projecting stabilized or marginally growing revenues capped by competition and regulatory factors.

FAQs

What is the primary clinical use of phendimetrazine tartrate?
It is used as a short-term appetite suppressant adjunct in obesity management.
Are there safety concerns associated with phendimetrazine?
Yes. It shares stimulant-like effects, potential for dependence, cardiovascular risks, and is regulated as a controlled substance.
What are the main competitors to phendimetrazine in the obesity market?
Recent therapies like semaglutide, lorcaserin, and combination drugs incorporating bupropion/naltrexone outperform older agents in efficacy and safety.
Is there ongoing R&D for new formulations or uses of phendimetrazine?
Limited, mainly focused on reformulations to improve safety and minimize abuse potential.
What are the key regulatory challenges facing phendimetrazine?
Strict regulations on stimulant drugs, abuse potential, and safety concerns restrict expanded use and innovation.

References

[1] Grand View Research, "Obesity Drugs Market Size, Share & Trends Analysis," 2023.
[2] U.S. Food and Drug Administration, "Obesity and Weight Management," 2022.
[3] Evaluate Pharma, "Pharmaceutical Market Data & Analysis," 2022.
[4] World Health Organization, "Obesity and Its Prevention," 2022.
[5] MarketWatch, "Global Appetite Suppressant Market Outlook," 2023.

US Patents:	0
Tradenames:	19
Applicants:	33
NDAs:	96
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	12
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	992
Drug Prices:	Drug price trends for PHENDIMETRAZINE TARTRATE
What excipients (inactive ingredients) are in PHENDIMETRAZINE TARTRATE?	PHENDIMETRAZINE TARTRATE excipients list
DailyMed Link:	PHENDIMETRAZINE TARTRATE at DailyMed

Drug Class	Sympathomimetic Amine Anorectic
Physiological Effect	Appetite Suppression Increased Sympathetic Activity

PHENDIMETRAZINE TARTRATE - Generic Drug Details

What are the generic sources for phendimetrazine tartrate and what is the scope of patent protection?

Summary for PHENDIMETRAZINE TARTRATE

Pharmacology for PHENDIMETRAZINE TARTRATE

US Patents and Regulatory Information for PHENDIMETRAZINE TARTRATE

Market Dynamics and Financial Trajectory for Phendimetrazine Tartrate